Health Insurance (Section 3C – Lutetium Therapeutic Nuclear Medicine Treatments) Determination 2025

The instrument pivots on several core concepts that define its practical operation.

• Clinically relevant service treated as scheduled item: Clause 5 directs that a "relevant service", provided in accordance with the instrument and as a clinically relevant service, is to be treated for the "relevant provisions" as if it were both a professional service and a medical service, and as if there were an item in the general medical services table or diagnostic imaging services table specifying a fee. The "relevant provisions" are defined broadly to include provisions of the Health Insurance Act 1973 and regulations, and the National Health Act 1953 and its regulations, that relate to medical services, professional services or items (cl 4(1), cl 5). This creates the legal fiction that the services are itemised for the purposes of existing regulatory and benefit processes.

• Defined clinical thresholds: The instrument defines "disease progression" for the purposes of two item numbers (16050 and 16055) using measurable criteria: a rise in PSA of greater than 2 ng/mL confirmed by two tests at least two weeks apart, or evidence of new soft tissue or bone metastases on diagnostic imaging computed tomography guided by established guidelines such as RECIST or PSMA-Imaging Criteria (cl 4(1)). This ties eligibility for at least some items to specific laboratory and imaging metrics rather than open clinical judgment alone.

• Credentialling and referral gatekeepers: The instrument imposes credential and referral requirements. Clause 8 conditions the applicability of Schedule 2 items on a referral from a specialist or consultant physician and on the service being provided by a "nuclear medicine credentialled specialist". The credential is a defined term describing a specialist or consultant physician whose name is included in a register provided to the Chief Executive Medicare by the JNMCAC under the Joint Nuclear Medicine Specialist Credentialling Program (cl 4(1), cl 8). That embeds an external credentialling process and an administrative register as preconditions.

• Multidisciplinary oversight: The instrument defines "formally convened neuroendocrine multidisciplinary board". The definition sets a minimum composition and specialist inclusion requirements: a board of relevant practitioners including specialists in medical oncology and nuclear medicine with experience in neuroendocrine neoplasms, endocrinology and surgery specialists, and at least one oncologist and one surgeon. That establishes a process requirement for decisions in certain clinical areas (cl 4(1)).

• Use of established imaging and assay standards: The instrument explicitly references PET, SPECT, SUV and PSMA as technical concepts. For disease progression it references established imaging assessment guidelines such as RECIST and Response Evaluation Criteria in PSMA-Imaging Criteria (cl 4(1)). This anchors eligibility to standardised and reproducible diagnostic criteria.

• Application to existing tables and provisions: Clauses 6 and 7 make specific parts of the General Medical Services Table and the Diagnostic Imaging Services Table operate as if the new items were included. Clause 9 empowers the Schedules to amend or repeal specified instruments. The effect is integration of the Determination into the statutory benefit architecture, subject to the detail in the Schedules (cl 6, cl 7, cl 9).

Taken together, these concepts convert a class of lutetium-related nuclear medicine services into services that fit within Medicare-style itemisation and administrative control, while imposing procedural requirements (referral, credentialling, multidisciplinary review) and clinical thresholds for particular items.

The instrument establishes legal roles and a range of actors who will be affected in concrete ways.

• Patients receiving the specified services: Where a relevant service listed in the Schedules is provided "in accordance with this instrument" and as a clinically relevant service, the service is to be treated as if there were a scheduled item with a specified fee (cl 5). Patients therefore are directly affected through eligibility to access services that will be processed under Medicare-style item rules and fees, subject to the Schedules and to the application conditions in clause 8 for Schedule 2 items.

• Medical specialists and consultants: The Determination places duties and constraints on medical practitioners. For Schedule 2 items the patient must be referred by a specialist or consultant physician (cl 8(a)). The definition of "formally convened neuroendocrine multidisciplinary board" assigns a decision-making or advisory role to a group of specialists (cl 4(1)). Specialists will be affected as referral sources, as board members, or as responsible clinicians for the services.

• Nuclear medicine credentialled specialists: The instrument creates a class of practitioner, the "nuclear medicine credentialled specialist", whose inclusion on a register administered by the Chief Executive Medicare at the direction of the JNMCAC is a condition for providing Schedule 2 services (cl 4(1), cl 8). Practitioners who administer or supervise these services will need to secure and maintain credentialling through the Joint Nuclear Medicine Specialist Credentialling Program to ensure the items apply.

• The Joint Nuclear Medicine Specialist Credentialling Program and JNMCAC: These organisations are institutional gatekeepers. The definition requires that the credentialled specialist be on a register given to the Chief Executive Medicare by the JNMCAC. That means the JNMCAC’s credentialling processes, decisions and the register it provides will determine which practitioners are eligible to provide Schedule 2 services under the item rules (cl 4(1), cl 8).

• Chief Executive Medicare and Commonwealth administrators: The instrument refers to the Chief Executive Medicare as the recipient of the credentialling register, and it operates by integrating items into the statutory tables used by administrators (cl 4(1), cl 5, cl 6, cl 7). Administrative officers will therefore be responsible for applying the determination operationally, maintaining and recognising the credentialling register, and processing claims under the relevant provisions of the Act and the National Health Act 1953.

• Providers of diagnostic imaging and nuclear medicine facilities: The instrument ties diagnostic imaging criteria to eligibility and references imaging modalities such as PET and CT. Facilities that provide PET/CT and SPECT imaging or that undertake radionuclide therapies will be affected by the need to meet documentation, credential and specialist requirements embedded in the definitions and clauses.

• Contracting and billing staff: Because the Determination treats services as if they were scheduled items with State-specific fees in the Schedules, billing, claiming and reconciliation staff will need to apply the Schedules once issued and to validate referral and credential prerequisites when processing Schedule 2 items (cl 5, cl 8).

• Other instruments and schedules: Clause 9 indicates that Schedules to the Determination will amend or repeal instruments specified in those Schedules. Entities subject to those instruments, including providers and administrators, will be affected when the Schedules take effect (cl 9).

In aggregate, the instrument distributes operational responsibility across patients, credentialled specialists, multidisciplinary boards, administrative registers, and Medicare executives. The practical gatekeepers for access to Schedule 2 services are the referring specialist and the presence of a nuclear medicine credentialled specialist on the register supplied to the Chief Executive Medicare (cl 8, cl 4(1)).

The Determination sets out duties and conferred rights in procedural and definitional terms.

Duties

• Provide the service "in accordance with this instrument" and as a clinically relevant service: Clause 5 conditions the treatment of the service as a scheduled item on the service being provided in accordance with the instrument and as a clinically relevant service. Providers therefore must ensure that service delivery complies with the instrument’s terms and any conditions in the Schedules in order to rely on the statutory treatment in clause 5.

• Referral requirement for Schedule 2 items: Clause 8(a) requires that a patient be referred by a specialist or consultant physician for items in Schedule 2 to apply. It is therefore a duty on referring practitioners to make such referrals where appropriate and on providers to verify referral status before applying the item.

• Provision by a nuclear medicine credentialled specialist: Clause 8(b) requires Schedule 2 services to be provided by a "nuclear medicine credentialled specialist" as defined in clause 4(1). This is a duty to ensure the provider is on the register given to the Chief Executive Medicare by the JNMCAC.

• Multidisciplinary board composition in certain contexts: The definition of "formally convened neuroendocrine multidisciplinary board" imposes a duty on the board that it include specified specialties and at least one oncologist and one surgeon. Where the instrument or the Schedules require such a board for decision-making or eligibility, providers must ensure the board meets those composition requirements (cl 4(1)).

• Use of defined diagnostic criteria and tests: For items tied to "disease progression" (items 16050 and 16055), the instrument requires adherence to the specific PSA and imaging criteria in the definition (cl 4(1)). That imposes a duty on clinicians to document laboratory and imaging evidence to the thresholds specified.

Rights and benefits

• Treatment as a scheduled item for benefit and regulatory purposes: Clause 5 confers a practical right: where a service is provided in accordance with the instrument it will be treated as if it were a professional and medical service and as if an item specifying a State fee existed in the appropriate schedule. That right will operate in relation to the "relevant provisions" and, by implication, will enable providers and patients to rely on the statutory mechanisms linked to scheduled items (cl 5).

• Inclusion of items in application provisions of the tables: Clauses 6 and 7 give the items the same operational status as if they were physically listed in specified subclauses of the General Medical Services Table and the Diagnostic Imaging Services Table. That is a right to be processed under the administrative and billing frameworks those clauses carry (cl 6, cl 7).

Administrative duties

• Credential maintenance and register management: Nuclear medicine specialists who wish to provide Schedule 2 items must ensure their name is included on the register administered through the JNMCAC and given to the Chief Executive Medicare. The JNMCAC’s processes thus become an administrative duty for the practitioner to remain eligible (cl 4(1), cl 8).

• Record-keeping and reporting: The instrument defines "report" as a report prepared by a medical practitioner (cl 4(1)). Although it does not prescribe report content, the definition and the disease progression criteria imply a duty to prepare and retain reports and documentation sufficient to demonstrate compliance with the instrument’s thresholds and procedural requirements.

Rights of administrators

• Power to apply relevant provisions: The Chief Executive Medicare and other administrators will exercise the application of existing statutory provisions to these services once treated as scheduled items under clause 5. That confers an administrative remit to process claims, recognise credentialling and apply any regulatory obligations in the "relevant provisions" (cl 5, cl 4(1)).

The instrument does not itself create financial entitlements in the text provided beyond instructing that fees specified in the Schedules are to be treated as if they were listed in the tables. The operative financial details will be in the Schedules, which are referenced but not included in the provided text (cl 5, cl 9).

The instrument does not itself prescribe specific penalties or a bespoke enforcement regime. It relies on the existing statutory framework to which it connects the services.

• No express penalties in the Determination text: The Determination, as reproduced, contains no clauses creating criminal or civil penalties, infringement notices, or administrative sanctions (full text). It therefore does not on its face create new penalty offences or specify penalty amounts.

• Enforcement by existing statutory provisions: Clause 5 operates by treating services as if scheduled items exist for the "relevant provisions". The "relevant provisions" include all provisions of the Health Insurance Act 1973 and regulations made under it, and the National Health Act 1953 and regulations made under that Act, that relate to medical services, professional services or items (cl 4(1), cl 5). Enforcement, compliance checks, and any penalties that might attach to improper claims or non-compliance will therefore be applied under those pre-existing statutory provisions rather than under new sanctions created by this Determination.

• Administrative downside of non-compliance: Although the Determination does not itself set fines, a practitioner who fails to meet the instrument’s conditions (for example by providing a Schedule 2 service without being a nuclear medicine credentialled specialist or without an appropriate referral) will not be able to treat the service as a scheduled item under clause 5. The practical consequence is that the provider and patient may not be able to rely on the billing and benefit treatment that clause 5 provides; administrators may reject claims or require different handling under the "relevant provisions". Those claim-processing consequences flow from the instrument’s linking into the statutory items framework rather than from penalties created by the Determination.

• Delegated administrative decisions: The Determination calls for a register to be given to the Chief Executive Medicare by the JNMCAC. That creates a delegated administrative checkpoint where the Chief Executive Medicare will recognise credentialling status. Any dispute about inclusion on the register, recognition of credentials or processing of claims will be resolved under administrative processes established by Medicare and under the "relevant provisions" that govern claims, audits and sanctions (cl 4(1), cl 8).

• Enforcement risk areas implicit in the text: The text raises potential enforcement focal points that administrators will likely monitor using existing statutory tools: whether services were provided "in accordance with this instrument", whether Schedule 2 eligibility conditions were met (specialist referral and credentialled provider), and whether clinical thresholds such as the defined "disease progression" were met where relevant. These matters are enforceable by audit, claim rejection and any penalties available under the Health Insurance Act and National Health Act frameworks rather than by new penalties in the Determination itself (cl 5, cl 8).

In short, enforcement and penalties will flow from the existing statutory and administrative regimes to which the Determination imports service treatment, not from the Determination directly. The Determination creates compliance gates that the administrative system will enforce through its ordinary mechanisms.

The Determination is explicitly integrative. It operates by mapping a set of services into the existing legislative architecture under the Health Insurance Act 1973 and the National Health Act 1953.

• Made under subsection 3C(1) of the Health Insurance Act: Clause 3 records the instrument’s source of authority as subsection 3C(1) of the Health Insurance Act 1973. That anchors the Determination as an exercise of power under that Act (cl 3). The instrument therefore sits within the Health Insurance Act’s regulatory field and is intended to operate by reference to it.

• Definition of "relevant provisions": Clause 4(1) defines "relevant provisions" to include all provisions of the Act and regulations made under it, and the National Health Act 1953 and regulations made under that Act, relating to medical services, professional services or items. The Determination therefore imports the operational effect, regulatory definitions, and enforcement tools of both Acts into its operation (cl 4(1)).

• Treatment as if items existed in the tables: Clause 5 treats specified relevant services as if they were both a professional service and a medical service and as if items existed in the general medical services table or the diagnostic imaging services table specifying a fee in relation to each State (cl 5). Clauses 6 and 7 push this further by making specified clauses of those Tables have effect as if the items in Schedules 1 and 2 were actually specified in those clause locations. This means the Determination integrates new services into the billing, claiming and item-based regulatory mechanisms that operate under the Health Insurance Act and the tables and subclauses referenced (cl 6, cl 7).

• Administrative registers and credentialling program: The Determination depends on the Joint Nuclear Medicine Specialist Credentialling Program and the JNMCAC to create and maintain a register that is to be given to the Chief Executive Medicare (cl 4(1)). That introduces inter-instrument administrative linkages between credentialling programmes and Medicare's administrative role. The interaction requires the JNMCAC to supply the register and Medicare to recognise it for the purposes of Schedule 2 items.

• Interaction with diagnostic standards and clinical guidelines: The definition of "disease progression" refers to diagnostic imaging assessments per established guidelines such as RECIST and PSMA-Imaging Criteria (cl 4(1)). Those external clinical guidelines will interact with the Determination by providing the benchmarks against which eligibility is measured. Although the instrument references these guidelines, it does not itself adopt or reproduce them; it relies on them as standards to be applied in decision-making and documentation.

• Schedules may amend or repeal other instruments: Clause 9 provides that each instrument specified in a Schedule to this Determination is amended or repealed as set out in the applicable items in the Schedule. Therefore the Determination is capable of modifying the existing statutory and regulatory landscape by altering other legislative instruments through its Schedules (cl 9). The Schedules themselves will determine the precise amendments to other instruments.

• Definitions and cross-referencing: The Determination uses terms that are already defined in subsection 3(1) of the Health Insurance Act, such as "clinically relevant service", "item", "professional service", "diagnostic imaging services table" and "general medical services table" (cl 4(1) note). This cross-reference ensures consistent statutory meaning across instruments and indicates that the Determination's operational effect will be interpreted through the Act’s existing definitions.

Taken together, the Determination functions by folding the specified lutetium-related nuclear medicine services into a pre-existing statutory and regulatory framework, relying on administrative registers, clinical guidelines and the item tables used by Medicare and related statutory instruments.

The provided instrument text contains limited material on prior amendments or modifications. What the Determination itself establishes about amendment mechanics is as follows.

• Instrument name and date reference: The Determination identifies itself as the Health Insurance (Section 3C - Lutetium Therapeutic Nuclear Medicine Treatments) Determination 2025 (cl 1). The presence of a year in the instrument title situates it as an instrument made in 2025, but the text does not set out any earlier versions, revocations or replacement history.

• Power to amend other instruments through Schedules: Clause 9 provides that each instrument specified in a Schedule to this Determination is amended or repealed as set out in the applicable items in the Schedule, and any other item in a Schedule has effect according to its terms (cl 9). This means the Determination is a vehicle not only to prescribe new item treatment but to change existing instruments through its Schedules. The actual amendments are contained in the Schedules, which are referenced but not included in the provided text.

• No express past amendments listed in the reproduced text: The text supplied contains no history section, no schedule listings, and no express record of prior amendments to this Determination itself. There is no list of instruments amended by previous versions. Therefore, based on the material provided, there is no internal amendment history recorded in the text to summarise.

• Amendment mechanism remains available: Because clause 9 empowers Schedules to amend or repeal instruments specified in them, any amendment history of other instruments effected by this Determination would be visible only through the Schedules. The text as provided implies that the operative content that effects administrative and fee changes will be in the Schedules and that any subsequent amendment or revocation of those Schedules would follow the ordinary legislative and executive processes provided for under the Health Insurance Act and associated legislative instruments, although those processes are not detailed in the provided text.

• Relationship to the Health Insurance Act machinery: The Determination was made under subsection 3C(1) of the Health Insurance Act 1973 (cl 3). Any future amendment or revocation of this Determination would necessarily follow the statutory procedures attached to the making and amending of determinations under the relevant provision of the Act, but the text does not set out those procedures.

In short, the provided text shows the Determination’s name, date and the capacity in which it was made, and it provides for Schedules to amend or repeal other instruments. It does not, in the extract provided, include a record of prior amendments to itself or to specific instruments because the relevant Schedules are not present in the text supplied.

The copy of the Determination provided contains no references to litigation, judicial interpretation, or case law. It does not list any decisions that have interpreted its terms, nor does it include any annotated history of disputes. Therefore the instrument, as reproduced, has no litigation history recorded within it.

That absence of litigation information has practical implications for how its clauses might be contested or litigated in future.

• Likely focal points for judicial interpretation: Although no cases are cited, several textual features of the Determination create potential areas where courts or tribunals could be asked to interpret the instrument if disputes arise. These include the phrases "in accordance with this instrument" and "as a clinically relevant service" in clause 5, whose scope is not exhaustively defined in the text and could be litigated in a claims or audit dispute; the requirement that services in Schedule 2 be provided by a "nuclear medicine credentialled specialist" and the administrative import of the credentialling register supplied by the JNMCAC; and the definitional thresholds for "disease progression" for items 16050 and 16055 in clause 4(1). Any of these could be contentious in a claim denial, audit, or administrative review context.

• Administrative review and merits review pathways: The Determination assigns administrative tasks to the Chief Executive Medicare and to credentialling bodies. If claims are rejected or practitioners are excluded from the register, affected parties may seek administrative or merits review under the statutory regimes that apply to Medicare decisions. The Determination itself does not set out dispute resolution mechanisms; hence existing review mechanisms in the Health Insurance Act and National Health Act frameworks will likely be the routes for challenge.

• Evidence and standard of review issues: Litigation or review proceedings would likely engage evidential questions based on the specification of diagnostic criteria such as PSA thresholds and imaging findings. Courts or tribunals would be asked to assess whether clinicians applied those thresholds correctly or whether evidence met the defined standards. The Determination’s incorporation by reference of external imaging guidelines such as RECIST or PSMA-Imaging Criteria could require expert evidence about the application of those guidelines.

• No precedential guidance from the instrument text: Since no litigation history is provided, practitioners and administrators must rely on the plain language of the Determination and on the "relevant provisions" of the Health Insurance Act and the National Health Act to understand enforcement and dispute resolution. That means first-instance administrative decisions and internal review processes are likely to form the initial body of interpretation if disputes emerge.

Because there are no cases or litigation cited in the text, anyone seeking to understand how the Determination has been interpreted must look to subsequent administrative decisions, tribunal determinations or court judgments post-dating the instrument. The instrument itself offers no litigation history for guidance.

The Determination contains several features that create practical risks, uncertainties and implementation frictions that practitioners and administrators should note.

• Key operative detail in Schedules not included here: The text supplied references Schedule 1 and Schedule 2 and states that fees for items will be specified in the Schedules (cl 5, cl 6, cl 7, cl 9). The Schedules are the operative place where item numbers, precise service descriptions and State-specific fees will be set. Absent the Schedules, practitioners cannot determine the exact item descriptions, fee amounts, or which instruments are to be amended or repealed. This creates uncertainty about billing and financial planning until the Schedules are published.

• Narrowly defined "disease progression": For items 16050 and 16055 the Determination defines "disease progression" as either a rise in PSA of greater than 2 ng/mL confirmed by two tests at least two weeks apart, or evidence of new soft tissue or bone metastases on diagnostic CT guided by established guidelines such as RECIST or PSMA-Imaging Criteria (cl 4(1)). That is a precise threshold; clinicians whose clinical judgment suggests treatment outside those thresholds may find that, for the purposes of these items, the service does not meet the Determination’s definition and so cannot be treated as a scheduled item. The requirement for two tests minimum two weeks apart could be a logistical constraint in rapidly evolving clinical situations.

• Referral and credential requirement for Schedule 2: Clause 8 conditions Schedule 2 items on both a specialist or consultant physician referral and provision by a nuclear medicine credentialled specialist (cl 8). If either condition is not satisfied , for example because a practitioner is practising while awaiting credentialling, or a referral pathway is not followed , the item will not apply and the claim may be processed differently. The requirement to be on a register that the JNMCAC supplies to the Chief Executive Medicare adds an administrative dependency external to the treating institution.

• Dependency on an external credentialling programme: The Determination makes eligibility contingent on the JNMCAC register. If credentialling processes are slow, inconsistent, or limited in participant numbers, capacity to provide Schedule 2 services under the item rules may be constrained. The instrument gives the JNMCAC a gatekeeping role without setting the procedures or timelines for credentialling in the Determination text.

• Ambiguities in who "provides" a service: Clause 8 requires that the service be provided by a nuclear medicine credentialled specialist. The Determination does not elaborate what "provided by" means , whether it requires the credentialled specialist to personally perform the procedure, supervise it in person, be the responsible clinician, or simply be part of a multi-disciplinary team. That ambiguity may create disputes about claim validity, particularly in settings where technicians or other professionals deliver aspects of the service under oncologist or nuclear medicine oversight.

• "Formally convened neuroendocrine multidisciplinary board" composition rigidity: The definition requires inclusion of particular specialties and at least one oncologist and one surgeon (cl 4(1)). In smaller centres or referral networks where such convening is operationally difficult, meeting the formal composition requirements may be challenging, delaying access or complicating documentation. The Determination does not specify procedures for virtual or cross-institutional boards.

• Reliance on external clinical guidelines: The Determination references RECIST and PSMA-Imaging Criteria for imaging-based disease progression determinations (cl 4(1)). Those guidelines may be updated over time. The Determination does not specify which edition or version governs, creating potential interpretive disputes about which guideline version to apply.

• No specified reporting content: The term "report" is defined simply as a report prepared by a medical practitioner (cl 4(1)). The Determination does not prescribe the content, format or retention period for reports. This leaves operational discretion to administrators about what documentary evidence suffices to demonstrate compliance.

• Integration into item tables could lead to claim rejections: Because the Determination treats services as if items exist in the tables only when the service is provided "in accordance with this instrument" (cl 5), missing any condition in the Determination or in the Schedules could lead to claim rejection or reclassification. Providers must therefore verify each precondition before submitting claims.

These "gotchas" flow directly from the Determination’s design choices: the centrality of the Schedules, reliance on external credentialling, precise but narrow clinical definitions, and minimal prescriptive detail on certain administrative processes.

This section sets out practical steps, grounded in the Determination’s text, that clinicians, providers and administrators should take to align operations with the instrument.

1. Obtain and review the Schedules immediately

• The Determination’s operative item descriptions and State-specific fees are located in Schedule 1 and Schedule 2 and in any instrument amendments those Schedules effect (cl 5, cl 6, cl 7, cl 9). Before billing or claiming under the Determination, obtain the Schedules and map each service provided to the precise item numbers, fees and any ancillary conditions specified there.

2. Check credentialling status and register inclusion

• For any Schedule 2 services, ensure the treating practitioner is a "nuclear medicine credentialled specialist", that their name appears on the register given to the Chief Executive Medicare by the JNMCAC, and that the credentialling is current (cl 4(1), cl 8). Communicate with the JNMCAC to understand the Joint Nuclear Medicine Specialist Credentialling Program’s application, documentation and renewal requirements.

3. Ensure appropriate referrals for Schedule 2 items

• Verify and retain the referral from a specialist or consultant physician before providing Schedule 2 services, because the item will not apply unless the patient was referred by such a practitioner (cl 8(a)). Implement administrative checks at booking and at the time of service to capture referral documentation.

4. Implement multidisciplinary board processes where required

• If the service requires review by a "formally convened neuroendocrine multidisciplinary board", establish procedures to convene such a board that meet the Determination’s composition requirements: include specialists in medical oncology and nuclear medicine experienced in neuroendocrine neoplasms, endocrinology and surgery specialists, and ensure at least one oncologist and one surgeon attend (cl 4(1)). Document meeting minutes, attendance and recommendations to create an auditable trail.

5. Document clinical thresholds and diagnostic evidence rigorously

• For items tied to "disease progression" (items 16050 and 16055), document the PSA test results (showing a rise greater than 2 ng/mL confirmed by two tests at least two weeks apart) or CT imaging evidence of new metastases using the referenced guidelines (RECIST or PSMA-Imaging Criteria) (cl 4(1)). Maintain contemporaneous reports and imaging records that explicitly reference the criteria applied.

6. Clarify provider roles and supervision arrangements

• Because the Determination conditions apply when the service is "provided by" a credentialled specialist (cl 8(b)), clarify whether credentialled specialists must personally perform, supervise or be responsible for the care. Where practice involves delegation to technicians or trainees, document the credentialled specialist’s supervisory role and responsibility to create defensible evidence that the Determination’s provider condition is met.

7. Align billing workflows with the item treatment model

• Treat services as if they are scheduled items only after confirming all preconditions. Configure practice management and billing systems to require confirmation of credentialling and referral status before generating claims for Schedule 2 items. Train coding and accounts staff to apply the Schedules and to recognise that failure to satisfy the Determination’s conditions may invalidate claims.

8. Maintain robust reporting and retention practices

• Although the Determination defines "report" simply as a report prepared by a medical practitioner (cl 4(1)), prepare structured reports that include the clinical rationale, test results, imaging interpretation referencing the applicable guidelines, board minutes where relevant, and identity of the credentialled specialist. Retain these records for the periods required under the "relevant provisions" in the Health Insurance Act and the National Health Act frameworks.

9. Liaise with Medicare and the JNMCAC on operational queries

• Because the register is to be provided to the Chief Executive Medicare by the JNMCAC (cl 4(1)), engage early with both organisations to clarify processes for register updates, dispute resolution about inclusion, and claim processing. Obtain point-of-contact details and escalate administrative uncertainties before services are delivered.

10. Prepare for audit and administrative review

• The Determination’s effect depends on subsequent application of the Health Insurance Act and National Health Act provisions (cl 4(1), cl 5). Expect audits or reviews to probe whether services were provided "in accordance with this instrument" and whether clinical thresholds were met. Implement internal compliance checks and pre-claim validation to reduce the risk of claim denial or administrative challenge.

Following these steps aligns clinical practice and administrative processes with the conditions embedded in the Determination and reduces the risk that services will fail to be treated as scheduled items for the purposes of the "relevant provisions" in the Health Insurance Act and the National Health Act.